29.15

2.83% -0.85

After Hours: 29.15

Stoke Therapeutics Inc (STOK)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Stoke Therapeutics Inc stock is traded at $29.15, with a volume of 407.23K. It is down -2.83% in the last 24 hours and down -3.09% over the past month. Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Previous Close:

$30.00

Open:

$30.2

24h Volume:

407.23K

Relative Volume:

0.63

Market Cap:

$1.82B

Revenue:

$32.08M

Net Income/Loss:

$-169.77M

P/E Ratio:

-10.26

EPS:

-2.8418

Net Cash Flow:

$-147.70M

1W Performance:

-0.75%

1M Performance:

-3.09%

6M Performance:

-13.27%

1Y Performance:

+149.15%

1-Day Range:

$28.95

$30.33

1-Week Range:

$28.12

$30.54

52-Week Range:

$11.17

$40.22

Stoke Therapeutics Inc Stock (STOK) Company Profile

Name

Stoke Therapeutics Inc

Sector

Healthcare (1107)

Industry

Biotechnology (621)

Phone

781-430-8200

Address

45 WIGGINS AVENUE, BEDFORD, MA

Employee

170

Twitter

@stoketx

Next Earnings Date

2026-05-07

Latest SEC Filings

STOK's Discussions on Twitter

Compare STOK vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
STOK Stoke Therapeutics Inc	29.15	1.87B	32.08M	-169.77M	-147.70M	-2.8418
VRTX Vertex Pharmaceuticals Inc	453.17	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.73	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	878.49	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	281.90	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	156.58	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-24-26	Initiated	Wolfe Research	Outperform
Feb-05-26	Initiated	Guggenheim	Buy
Jan-05-26	Resumed	Chardan Capital Markets	Buy
Jul-18-25	Initiated	Jefferies	Buy
Dec-20-24	Initiated	Chardan Capital Markets	Buy
Oct-14-24	Resumed	Leerink Partners	Outperform
Mar-26-24	Upgrade	TD Cowen	Market Perform → Outperform
Nov-20-23	Resumed	JP Morgan	Neutral
Jul-25-23	Downgrade	TD Cowen	Outperform → Market Perform
May-01-23	Upgrade	BofA Securities	Underperform → Neutral
Apr-26-23	Resumed	Canaccord Genuity	Buy
Jan-06-23	Downgrade	BofA Securities	Buy → Underperform
Oct-24-22	Upgrade	SVB Leerink	Mkt Perform → Outperform
Jan-31-22	Initiated	Jefferies	Buy
Dec-03-21	Initiated	BofA Securities	Buy
Nov-22-21	Upgrade	JP Morgan	Neutral → Overweight
May-18-21	Initiated	UBS	Neutral
May-10-21	Upgrade	Wedbush	Neutral → Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform
Feb-10-21	Downgrade	Wedbush	Outperform → Neutral
Dec-15-20	Resumed	H.C. Wainwright	Buy
Dec-11-20	Reiterated	Needham	Buy
Oct-23-20	Initiated	Cantor Fitzgerald	Overweight
Sep-29-20	Resumed	JP Morgan	Neutral
Sep-29-20	Initiated	Needham	Buy
Dec-18-19	Initiated	Wedbush	Outperform
Nov-12-19	Initiated	BTIG Research	Buy
Oct-25-19	Initiated	H.C. Wainwright	Buy
Jul-15-19	Initiated	Canaccord Genuity	Buy
Jul-15-19	Initiated	Cowen	Outperform
Jul-15-19	Initiated	Credit Suisse	Outperform
Jul-15-19	Initiated	JP Morgan	Overweight

View All

Stoke Therapeutics Inc Stock (STOK) Latest News

Jun 15, 2026

Stoke Therapeutics Stock (US86150R1023): Analyst Sentiment and Valuation Come Into Focus - AD HOC NEWS

Jun 15, 2026

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Jun 15, 2026

Jun 13, 2026

Rhenman & Partners Asset Management AB Lowers Position in Stoke Therapeutics, Inc. $STOK - MarketBeat

Jun 13, 2026

Stoke Therapeutics (NASDAQ:STOK) Trading Up 1.6%Should You Buy? - MarketBeat

Jun 13, 2026

Jun 08, 2026

STOK: Durable efficacy and cognitive gains position zorevunersen for a focused U.S. launch by 2028 - TradingView

Jun 08, 2026

The Technical Signals Behind (STOK) That Institutions Follow - Stock Traders Daily

Jun 08, 2026

Jun 05, 2026

Stoke Therapeutics (STOK) director receives grant of 17,786 stock options - Stock Titan

Jun 05, 2026

[Form 4] Stoke Therapeutics, Inc. Insider Trading Activity - Stock Titan

Jun 05, 2026

Stoke Therapeutics (STOK) director granted 17,786 stock options at $29.46 - Stock Titan

Jun 05, 2026

Stoke Therapeutics (STOK) director awarded 17,786 options at $29.46 strike - Stock Titan

Jun 05, 2026

Stoke Therapeutics (STOK) director granted options to buy 17,786 shares - Stock Titan

Jun 05, 2026

Stoke Therapeutics (STOK) director receives grant of 17,786 stock options at $29.46 - Stock Titan

Jun 05, 2026

Stoke Therapeutics (STOK) forms 'hammer chart pattern': Time for bottom fishing? - MSN

Jun 05, 2026

Jun 04, 2026

Stoke Therapeutics Stockholders Approve Directors and Governance Items - TipRanks

Jun 04, 2026

Stoke Therapeutics (NASDAQ: STOK) 2026 meeting elects all directors - Stock Titan

Jun 04, 2026

STOK: Lead therapy delivers durable seizure and cognitive benefits, with pivotal data due mid-2027 - TradingView

Jun 04, 2026

Stoke Therapeutics (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Yahoo Finance

Jun 04, 2026

Jun 03, 2026

Insider Sell Alert: Barry Ticho Sells Shares of Stoke Therapeutics Inc (STOK) - GuruFocus

Jun 03, 2026

Insider Sell Alert: Barry Ticho Sells Shares of Stoke Therapeuti - GuruFocus

Jun 03, 2026

Stoke Therapeutics (STOK) CMO sells 1,795 shares under 10b5-1 plan - Stock Titan

Jun 03, 2026

Stoke Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus

Jun 03, 2026

Jun 01, 2026

Stoke Therapeutics Advances Dravet Syndrome Clinical Trials Following Positive Results - asatunews.co.id

Jun 01, 2026